| Sekundarni jezik: | Angleški jezik | 
        
        
            | Sekundarni naslov: | Clinical course of HER-2 positive breast cancer patients | 
        
        
        
            | Sekundarni povzetek: | Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p | 
        
        
            | Sekundarne ključne besede: | Breast Neoplasms;Genetics;Neoplasm Staging;Genes, Erbb-2;Survival Analysis;Disease-Free Survival;Retrospective Studies;Preživetje, analiza;Brez bolezni, preživetje;Dojka, novotvorbe;Geni erB-2;Novotvorba, stadij;Retrospektivne študije; | 
        
            | URN: | URN:NBN:SI | 
        
            
        
        
           
        
           
        
           
        
           
        
           
        
            | Komentar vira: | Soavtorji: Š. Fink, S. Frković Grazio, H. Lešničar, A. Sadikov in T. Čufer;
BSDOCID143369; | 
        
           
        
           
        
            | Strani: | str. 94-98 | 
        
           
        
            | Letnik: | ǂLetn. ǂ12 | 
        
           
        
            | Zvezek: | ǂšt. ǂ2 | 
        
           
        
            | Čas izdaje: | 2008 | 
        
           
        
           
        
           
        
           
        
           
        
          
        
          
        
          
        
         
        
         
        
        
            | ID: | 10957171 |